Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -132.98% is in line with its 5-year average of -127.01%, near the high end of its 5-year range (-1667.29%–60.88%).
69.77% above its 12-month average of -439.93%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -67.61%.
EBITDA MARGIN
-132.98%
EBITDA MARGIN AVG TTM
-439.93%
EBITDA MARGIN AVG 3Y
-144.81%
EBITDA MARGIN AVG 5Y
-127.01%
EBITDA MARGIN AVG 10Y
-112.00%
EBITDA MARGIN AVG 15Y
-128.96%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+69.77%
CURRENT VS 3Y AVG
+8.17%
CURRENT VS 5Y AVG
-4.70%
CURRENT VS 10Y AVG
-18.73%
CURRENT VS 15Y AVG
-3.11%
CURRENT VS 20Y AVG
N/A
Xencor, Inc.
Market Cap
$1.80B
EBITDA Margin
-132.98%
TTM Avg
-439.93%
3Y Avg
-144.81%
5Y Avg
-127.01%
Market Cap
$1.80B
EBITDA Margin
-695.72%
TTM Avg
-791.65%
3Y Avg
-791.65%
5Y Avg
-791.65%
Market Cap
$1.82B
EBITDA Margin
31.38%
TTM Avg
29.77%
3Y Avg
26.47%
5Y Avg
27.37%
Market Cap
$1.82B
EBITDA Margin
-27.90%
TTM Avg
-7.22%
3Y Avg
-21.35%
5Y Avg
-40.43%
Market Cap
$1.79B
EBITDA Margin
-4034.86%
TTM Avg
-3070.57%
3Y Avg
-2386.79%
5Y Avg
-1872.66%
Market Cap
$1.85B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
Market Cap
$1.77B
EBITDA Margin
17.09%
TTM Avg
16.59%
3Y Avg
16.89%
5Y Avg
16.75%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xencor, Inc. (XNCR) | $1.80B | -132.98% | -439.93% | -144.81% | -127.01% |
| Novavax, Inc. (NVAX)vs › | $1.80B | 52.59% | 11.61% | -27.43% | -466.07% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.80B | -695.72% | -791.65% | -791.65% | -791.65% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 31.38% | 29.77% | 26.47% | 27.37% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | -27.90% | -7.22% | -21.35% | -40.43% |
| Absci Corporation (ABSI)vs › | $1.79B | -4034.86% | -3070.57% | -2386.79% | -1872.66% |
| Novocure Ltd (NVCR)vs › | $1.78B | -20.84% | -23.57% | -26.35% | -17.29% |
| Immunome, Inc. (IMNM)vs › | $1.85B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| Surgery Partners, Inc. (SGRY)vs › | $1.77B | 17.09% | 16.59% | 16.89% | 16.75% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 3.91% | 4.83% | 6.92% | 8.21% |
Gross Margin
91.6%
EBITDA Margin
-133.0%
Operating Margin
-141.3%
Net Margin
-155.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -67.61% |
| 2026-03-31 | -1667.29% |
| 2025-12-31 | -180.79% |
| 2025-09-30 | -213.96% |
| 2025-06-30 | -69.98% |
| 2025-03-31 | -123.70% |
| 2024-12-31 | 10.06% |
| 2024-09-30 | -293.00% |
| 2024-06-30 | -349.60% |
| 2024-03-31 | -322.74% |
| 2023-12-31 | -50.04% |
| 2023-09-30 | -25.57% |
| 2023-06-30 | -50.77% |
| 2023-03-31 | -308.51% |
| 2022-12-31 | -187.11% |
| 2022-09-30 | -132.28% |
| 2022-06-30 | -85.42% |
| 2022-03-31 | 33.50% |
| 2021-12-31 | 60.88% |
| 2021-09-30 | -199.70% |
| 2021-06-30 | 16.07% |
| 2021-03-31 | -41.32% |
| 2020-12-31 | -29.07% |
| 2020-09-30 | -43.19% |
| 2020-06-30 | -276.24% |
| 2020-03-31 | -22.86% |
| 2019-12-31 | -834.70% |
| 2019-09-30 | -60.69% |
| 2019-06-30 | -95.28% |
| 2019-03-31 | 70.79% |
| 2018-12-31 | -174.68% |
| 2018-09-30 | 5.05% |
| 2017-12-31 | -121.31% |
| 2017-09-30 | -224.74% |
| 2017-06-30 | -54.09% |
| 2017-03-31 | -348.13% |
| 2016-12-31 | -148.46% |
| 2016-09-30 | -113.59% |
| 2016-06-30 | 74.09% |
| 2016-03-31 | -88.95% |
| 2015-12-31 | 35.78% |
| 2015-09-30 | -286.55% |
| 2015-06-30 | -861.14% |
| 2015-03-31 | -418.38% |
| 2014-12-31 | -19.23% |
| 2014-09-30 | -725.47% |
| 2014-06-30 | -593.08% |
| 2014-03-31 | -157.83% |
| 2013-12-31 | -196.79% |
| 2013-09-30 | -54.05% |
| 2013-06-30 | -21.58% |
| 2013-03-31 | -284.16% |
| 2012-12-31 | -99.46% |
| 2012-09-30 | -119.92% |
